In the BioHarmony Drug Report Database

"Preview" Icon

Brexpiprazole

Rexulti, Rxulti (brexpiprazole) is a small molecule pharmaceutical. Brexpiprazole was first approved as Rexulti on 2015-07-10. It is used to treat major depressive disorder, schizophrenia, and schizophrenia spectrum and other psychotic disorders in the USA. It has been approved in Europe to treat schizophrenia. It is known to target D(2) dopamine receptor. Rexulti’s patents are valid until 2032-10-12 (FDA).

 

Trade Name

 

Rxulti
 

Common Name

 

brexpiprazole
 

ChEMBL ID

 

CHEMBL2105760
 

Indication

 

major depressive disorder, schizophrenia, schizophrenia spectrum and other psychotic disorders
 

Drug Class

 

Antiulcer agents (benzimidazole derivatives)

Image (chem structure or protein)

Brexpiprazole structure rendering